BioTime (BTX) Names New SVP, Head of Corporate Development
- Goldman sends Dow to record high, techs lift S&P, Nasdaq
- Oil hits 16-month high in buying rush after OPEC agreement
- Consolidated Communications (CNSL) to Acquire FairPoint Communications (FRP) in $1.5B Deal
- Pre-Open Stock Movers 12/05: (FRP) (GMED) (CHK) Higher; (CERC) (HDSN) (MRVL) Lower (more...)
- Burberry rejects multiple takeover offers from Coach: Financial Times
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
BioTime, Inc. (NYSE: BTX) announced that the company has appointed Jim Knight as Senior Vice President, Head of Corporate Development. He reports to Adi Mohanty, Co-Chief Executive Officer.
In his new role, Mr. Knight will oversee business development, portfolio strategy and strategic marketing. He brings more than 20 years of experience in creating portfolio value at publicly-traded companies including, Questcor Pharmaceuticals, Inc. and Elan Pharmaceuticals.
“Jim is a highly-accomplished professional with an extensive skill set and knowledge that is applicable immediately, as we have started reporting encouraging early clinical data on our key programs,” said Mr. Mohanty. “I’m confident that his track record of value creation, particularly during his time at Questcor, where he helped drive portfolio expansion that grew revenue from $150 million to more than $1 billion over a period of just four years, will assist us during this exciting juncture and help us create value for our shareholders.”
Most recently, Mr. Knight was the Vice President of Portfolio Strategy at Questcor from 2010 through 2014. Questcor was acquired by Mallinckrodt Pharmaceuticals for $5.6 billion in that year, and Mr. Knight stayed on for a transition and integration period through 2015. Prior to Questcor, Mr. Knight was at Elan Pharmaceuticals from 2001 to 2008, where he led a global strategic marketing team, working closely with collaborators at Biogen Inc. on the successful development and commercialization of Tysabri, a monoclonal antibody. He started his career in the research group at Biogen, before moving to sales and market analysis roles. Mr. Knight has a BS in Biology from the University of Massachusetts, Amherst and an MBA in High Technology from Northeastern University.
“I am excited to join the BioTime team,” said Mr. Knight. “The company’s proprietary pluripotent stem cells and HyStem delivery system have a growing body of data that support significant potential to deliver on revolutionary products. I feel confident that I can help accelerate the development of these products internally as well through appropriate partnerships.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LPL Financial (LPLA) Announces Retirement of LPL Financial LLC CEO Cassidy
- Marsh & McLennan's (MMC) Mercer Announces acquisition of Sirota Consulting
- ARIAD Pharma (ARIA) Announces Presentation of Brigatinib Phase 1/2, ALTA Trial Data; ORRs of 53% and 67% Noted
Create E-mail Alert Related CategoriesCorporate News, Management Changes, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!